Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Actimid enters phase II trial for prostate cancer

Nov. 3, 2003

Anti-EGFR antibody with ADCC-inducing activity

Oct. 31, 2003

Favrille raises financing to support phase II and III trials of FavId for NHL

Oct. 21, 2003

ACP-2127 advanced into preclinical testing

Oct. 20, 2003

Signal patent describes novel ER modulators for osteoporosis, cancer, etc.

Oct. 16, 2003

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Oct. 9, 2003

NeuTec seeks development partners for Mycograb for cancer

Oct. 8, 2003

Expansion of phase III Virulizin trial

Oct. 2, 2003

Telomerase-targeting vaccines in development at GemVax

Oct. 1, 2003

Maxim completes enrollment for phase III trial of Ceplene with IL-2

Sep. 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...